The study will explore the effect of HBsAg and other clinical factors on liver metastasis of colorectal cancer, and provide new research ideas and direction for further treatment of liver metastasis of colorectal cancer.

Retrospective analysis of Affiliated Hospital of Qingdao University Medical College in January 2010 to June 2011 with pathology confirmed 892 cases of colorectal cancer patients. The clinical data (including hepatitis B surface antigen, age, preoperative related laboratory examination, postoperative pathological results) were collected to determine whether the incidence of liver metastasis was affected.

There was no statistically significant difference compared to two groups of gender age, tumor location, tumor size, histological type, whether the stoma, serum albumin, serum bilirubin, ALP (χ²=0.359, Z=-1.631, χ²=0.003, χ²=1.223, χ²=0.619, χ²=0.516, Z=-3.235, Z=-0.106, Z=-0.328; P>0.05). HBsAg positive patients can significantly reduce the incidence of liver metastasis than negative patients, there was a significant statistical difference (χ²=5.809, P<0.05). In addition, the degree of liver metastasis and differentiation (χ²=14.165, P<0.01), the degree of infiltration (χ²=17.808, P<0.01) and the number of lymph node metastasis (χ²=41.798, P<0.01) , the difference was statistically significant. Multivariate logistic regression analysis showed that hepatitis B virus-positive patients with liver metastasis occurred low, and poorly differentiated, high degree of invasion, lymph node metastasis and high liver metastases.

Hepatitis B virus surface antigen positive will reduce the incidence of liver metastases. The lower degree of differentiation, the higher degree of infiltration, the number of lymph node metastasis, are the factors more prone to liver metastasis.